pennystockhaven
  • Facebook
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » DARA BioSciences (DARA): Granted Exclusive U.S. Commercial Rights to Gelclair®

DARA BioSciences (DARA): Granted Exclusive U.S. Commercial Rights to Gelclair®

Posted on September 13, 2012 by PennyStockHaven in Commentary, Stock Market News - 1 Comment
Penny markets DARA BioSciences logo

DARA BioSciences, Inc. (DARA) announced today that company entered into an exclusive agreement with The Helsinn Group of Switzerland for U.S. commercial rights to Gelclair®.

DARA plans to launch Gelclair, FDA-cleared product indicated for the treatment of oral mucositis, in the first quarter of 2013.

Oral mucositis market is approximately 400,000 patients annually according to the research of The American Cancer Society. The National Cancer Institute estimates that almost 100 percent of patients receiving radiation therapy for head and neck cancers experience oral mucositis, as do 80 percent of patients undergoing hematopoietic stem cell transplantation and 40 percent of patients receiving standard-dose chemotherapy. DARA’s Gelclair is a topical gel used to coat and protect the oral cavity to reduce pain.

David J. Drutz, MD, DARA’s chief executive officer, commented:

The exclusive agreement with Helsinn for rights to commercialize Gelclair is a significant milestone that provides us with an important commercial product in an area of significant medical need. Hundreds of thousands of cancer patients suffer from oral mucositis each year. Helsinn offers DARA a respected partner with extensive experience in the oncology supportive care market. Our joint undertaking also provides the potential opportunity for a meaningful and long-term commercial and developmental relationship between our two companies.

DARA BioSciences’s pipeline:

penny stock DARA products


Penny markets DARA BioSciences logoDARA BioSciences, Inc.
8601 Six Forks Road
Suite 160
Raleigh, NC 27615
Tel: 919-872-5578
Fax: 919-861-0239

DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products.

DARA biopharma, DARA BioSciences, Nasdaq penny stock

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • CVR Partners, LP (NYSE: UAN): the dividend play

    February 26, 2023
  • Sotera Health

    Sotera Health Company (NASDAQ:SHC): hard road ahead

    February 21, 2023
  • ZIM Integrated Shipping Services (NYSE:ZIM) uphill movement

    February 20, 2023
  • Carvana Co. (NYSE: CVNA) way to go… down

    February 17, 2023
  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2021 PennyStockHaven.com. All Rights Reserved